Breakthrough Gene Therapy Shows Promise in Huntington's Disease

An innovative gene therapy administered only once has demonstrated significant potential in decelerating the progression of Huntington's disease, according to findings from a preliminary study.

The treatment, known as AMT-130, was shown to slow down disease progression by an impressive 75% over three years for patients receiving a higher dosage, compared to those who remained on conventional care, as reported by the research team. Although these initial findings are hopeful, the journey toward regulatory approval could be lengthy, with the earliest submission to the FDA anticipated no sooner than 2026.

UCL professor Ed Wild commented, "This development is transformative. For instance, one of my patients, previously forced into early retirement due to the disease, has now successfully resumed employment."

In the U.S., Huntington's disease impacts roughly 100,000 individuals. A defective gene provokes the creation of harmful proteins that deteriorate brain cells, with children of affected parents facing a 50% risk of inheriting the condition. The disorder typically manifests in middle age, leading to challenges in motor functions, cognition, and emotional state, and tends to worsen over 15 to 20 years.

Innovative Delivery Mechanism

The novel treatment harnesses a benign virus to impart genetic directives into the brain, aiming to deactivate the protein responsible for neural degeneration. Unlike existing therapies that target symptom management, AMT-130 is envisioned as a single administration treatment with lifelong effects.

Professor Sarah Tabrizi, who leads scientific counsel for the trial at UCL, expressed her enthusiasm: "The trial demonstrated clear, statistically meaningful benefits in terms of slowing the disease's course." She further noted that it holds potential for aiding patients in maintaining daily capacities and prolonging their productive engagements.

Preliminary Study Details

Involving 29 participants, the study observed that 12 of them were given high doses of the therapy across three years. Efficacy was gauged through advanced imaging and spinal fluid biomarkers, both indicating marked decreases in neural damage.

Despite promising outcomes, experts emphasize the need for larger-scale trials. Delivering this treatment involves intricate brain surgery for direct application to affected areas, yet participants tolerated the procedure with side effects deemed manageable.

Should it receive approval, AMT-130 will be the first treatment to effectively slow Huntington's disease progression, rather than merely addressing symptoms. However, securing FDA approval demands extensive, further testing to verify the treatment's safety and efficacy.

While these findings are yet to undergo peer review or be published in a medical journal, they will be discussed at an upcoming significant medical conference.